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 Abstract 
Nucleic acid reagents including small interfering RNA (siRNA) and plasmid DNA 
are important tools for the study of mammalian cells, and are also promising starting 
points for the development of new therapeutic agents.  Realizing their full potential, 
however, requires nucleic acid delivery reagents that are simple to prepare, effective across 
many mammalian cell lines, and non-toxic.  We recently described the extensive surface 
mutagenesis of proteins in a manner that dramatically increases their net charge and 
showed that this “supercharging” of proteins can impart strong resistance to aggregation.  
Here we report that superpositively charged green fluorescent proteins, including a variant 
with a theoretical net charge of +36 (+36 GFP), can penetrate a variety of mammalian cell 
lines.  Internalization of +36 GFP is dependent on non-specific electrostatic interactions 
with sulfated proteoglycans present on the surface of most mammalian cells.  When +36 
GFP is mixed with siRNA, protein-siRNA complexes ~1.7 µm in diameter are formed.  
Addition of these complexes to five human and murine cell lines, including four that are 
resistant to cationic lipid-mediated siRNA transfection, results in potent siRNA delivery.  
In four of these five cell lines, siRNA transfected by +36 GFP suppresses target gene 
expression.  In addition, we show that +36 GFP is resistant to proteolysis, is stable in the 
presence of serum, and extends the serum half-life of siRNA and plasmid DNA with which 
it is complexed.  A variant of +36 GFP can mediate DNA transfection in a manner that 
enables plasmid-based gene expression.  These findings indicate that superpositively 
charged proteins can overcome some of the key limitations of currently used transfection 
agents. 
\body 
Introduction 
Commercially available cationic lipid reagents are typically used to transfect nucleic 
acids in mammalian cell culture.  The effectiveness of these reagents, however, varies greatly by 
cell type.  A number of cell lines including some neuron, T-cell, fibroblast, and epithelial cell 
lines have demonstrated resistance to common cationic lipid transfection reagents (1-4).  
Alternative transfection approaches including electroporation (5) and virus–mediated siRNA 
delivery (6, 7) have been used; however, these methods can be cytotoxic or perturb cellular 
function in unpredictable ways. McNaughton, Cronican, and Liu-3 
Recent efforts to address the challenge of nucleic acid delivery have resulted in a variety 
of nucleic acid delivery platforms.  These methods include lipidoids (8), cationic polymers (9), 
inorganic nanoparticles (10), carbon nanotubes (11), cell-penetrating peptides (12, 13), cationic 
protein–antibody fusions (14, 15), and chemically modified nucleic acids (16).  Each of these 
methods offers benefits for particular applications; in most cases, however, questions regarding 
cytotoxicity, ease of preparation, stability, or generality across different cell lines remain.  Easily 
prepared reagents capable of effectively delivering nucleic acids to a variety of cell lines without 
significant cytotoxicity therefore are of considerable interest. 
We recently described resurfacing proteins without abolishing their structure or function 
through the extensive mutagenesis of non-conserved, solvent-exposed residues (17).  When the 
replacement residues are all positively or all negatively charged, the resulting “supercharged” 
proteins can retain their activity while gaining unusual properties such as robust resistance to 
aggregation and the ability to bind oppositely charged macromolecules.  For example, we 
reported that a green fluorescent protein with a +36 net theoretical charge (+36 GFP) was highly 
aggregation-resistant, could retain fluorescence even after being boiled and cooled, and 
reversibly complexed DNA and RNA through electrostatic interactions. 
A variety of cationic peptides and proteins have been observed to penetrate mammalian 
cells (18-24).  We hypothesized that superpositively charged proteins such as +36 GFP might 
also associate with negatively charged components of the cell membrane in a manner that results 
in cell penetration.  Given the ability of these proteins to reversibly bind nucleic acids, we further 
speculated that superpositively charged proteins may also deliver pre-complexed nucleic acids 
including siRNA or plasmid DNA into mammalian cells. 
Here we describe the cell-penetrating and nucleic acid transfection activities of 
superpositively charged GFP variants.  We found that +36 GFP potently enters cells through 
sulfated peptidoglycan-mediated, actin-dependent endocytosis.  When pre-mixed with siRNA, 
+36 GFP forms monodisperse particles that deliver siRNA effectively and without cytotoxicity 
into a variety of cell lines, including several known to be resistant to cationic lipid-mediated 
transfection.  The siRNA delivered into cells using +36 GFP was able to effect gene silencing in 
four out of five mammalian cell lines tested.  Comparison of the siRNA transfection ability of 
+36 GFP with that of several synthetic peptides of comparable charge magnitude suggests that 
the observed mode of siRNA delivery requires features of +36 GFP that are not present among 
cationic peptides.  When fused to an endosomolytic peptide, +36 GFP is also able to transfect McNaughton, Cronican, and Liu-4 
plasmid DNA into several mammalian cell lines in a manner that enables plasmid-based gene 
expression.  In addition, we observed that +36 GFP is stable in murine serum, and can 
significantly enhance the serum stability of siRNA and plasmid DNA to which it is complexed. 
 
Results 
Mammalian Cell Penetration by Supercharged GFPs.  We previously generated and 
characterized a series of resurfaced variants of “superfolder GFP” (sfGFP) (25) with theoretical 
net charges ranging from -30 to +48 that retain fluorescence (17).  The evaluation of the ability 
of these supercharged GFPs to penetrate mammalian cells requires a method to remove surface-
bound, non-internalized GFP.  We therefore confirmed that washing conditions known to remove 
surface-bound cationic proteins from cells (13) also effectively remove cell surface-bound 
superpositively charged GFP.  We treated HeLa cells with +36 GFP at 4° C, a temperature that 
allows +36 GFP to bind to the outside of cells but blocks internalization (vide infra).   Cells were 
washed three times at 4 °C with either PBS or with PBS containing heparin and analyzed by flow 
cytometry for GFP fluorescence.  Cells washed with PBS were found to have significant levels 
of GFP (presumably surface-bound), while cells washed with PBS containing heparin exhibited 
GFP fluorescence intensity very similar to that of untreated cells (Supporting Information Fig. 
S1).  These observations confirmed the effectiveness of three washes with heparin at removing 
surface-bound superpositively charged GFP. 
Next we incubated HeLa cells with 10-500 nM sfGFP (theoretical net charge of -7), -30 
GFP, +15 GFP, +25 GFP, or +36 GFP for 4 hours at 37 °C (Fig. 1A).  After incubation, cells 
were washed three times with PBS containing heparin and analyzed by flow cytometry.  No 
detectable internalized protein was observed in cells treated with sfGFP or -30 GFP.  HeLa cells 
treated with +25 GFP or +36 GFP, however, were found to contain high levels of internalized 
GFP.  In contrast, cells treated with +15 GFP contained 10-fold less internalized GFP, indicating 
that positive charge magnitude is an important determinant of effective cell penetration (Fig. 1B).  
We found that +36 GFP readily penetrates HeLa cells even at concentrations as low as 10 nM 
(Supporting Information Fig. S2).   
In order to test the generality of cell penetration by +36 GFP, we repeated these 
experiments using four additional mammalian cell types: inner medullary collecting duct 
(IMCD) cells, 3T3-L pre-adipocytes, rat pheochromocytoma PC12 cells, and Jurkat T-cells.  
Flow cytometry revealed that 200 nM +36 GFP effectively penetrates all five types of cells McNaughton, Cronican, and Liu-5 
tested (Fig. 1C).  Internalization of +36 GFP in stably adherent HeLa, IMCD, and 3T3-L cell 
lines was confirmed by fluorescence microscopy (vide infra).  Real-time imaging showed +36 
GFP bound rapidly to the cell membrane of HeLa cells and was internalized within minutes as 
punctate foci that migrated towards the interior of the cell and consolidated into larger foci, 
consistent with uptake by endocytosis. 
 
Mechanistic Probes of +36 GFP Cell Penetration.  To illuminate the mechanism by which +36 
GFP enters cells, we repeated the cell penetration experiments in HeLa cells under a variety of 
conditions that each blocks a different component of an endocytosis pathway (26, 27).  Cell 
penetration of +36 GFP was not observed when HeLa cells were cooled to 4°C prior to and 
during +36 GFP treatment (Fig. 2B).  This result suggests that uptake of +36 GFP requires an 
energy-dependent process, consistent with endocytosis (13).  We next evaluated the effects of 5 
μg/mL filipin or 25 µg/mL nystatin, small molecules known to inhibit caveolin-dependent 
endocytosis.  Neither inhibitor significantly altered +36 GFP internalization (Figs. 2C and 2D, 
respectively).  Treatment with chlorpromazine, a known inhibitor of clathrin–mediated 
endocytosis, similarly had little effect on +36 GFP cell penetration (Fig. 2E).  In addition, 
simultaneous treatment of HeLa cells with 50 nM +36 GFP and 10 μg/mL of fluorescently 
labeled transferrin, a protein known to be internalized in a clathrin–dependent manner (28), 
resulted in little GFP/transferrin colocalization (Fig. 2F).  Treatment with cytochalasin D, an 
actin polymerization inhibitor, however, significantly decreased +36 GFP cell penetration (Fig. 
2G).  Taken together, these results are consistent with a model in which +36 GFP uptake 
proceeds through an endocytotic pathway that is energy-dependent, requires actin 
polymerization, and does not require clathrin or caveolin. 
Based on previous studies (29) we hypothesized that anionic cell-surface proteoglycans 
might serve as receptors to mediate +36 GFP internalization.  Indeed, 80 mM sodium chlorate, 
an inhibitor of the ATP sulphurylase enzyme required to biosynthesize sulfated proteoglycans 
(30), completely blocked +36 GFP penetration (Fig. 2H).  Moreover, wild-type CHO cells (Fig. 
2I), but not proteoglycan-deficient CHO cells (PGD-CHO) that lack xylosyltransferase, an 
enzyme required for glycosaminoglycan synthesis (Fig. 2J), efficiently internalized +36 GFP.  
These findings suggest that +36 GFP penetration of mammalian cells requires binding to sulfated 
cell-surface peptidoglycans.  
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+36 GFP Binds siRNA and Delivers siRNA into a Variety of Mammalian Cell Lines.  We 
previously observed the ability of superpositively charged proteins to form complexes with DNA 
and tRNA (17).  In light of these results, we evaluated the ability of +15, +25, and +36 GFP to 
bind siRNA.  Using a gel-shift assay (31), we observed binding of +25 and +36 GFP to siRNA 
with a stoichiometry of ~2:1, while greater than five +15 GFP proteins on average were required 
to complex a single siRNA molecule (Fig. 3A).  In contrast, 100 equivalents of sfGFP did not 
detectably bind siRNA under the assay conditions.  
Next we examined the ability of +15, +25, and +36 GFP to deliver bound siRNA into 
HeLa cells.  A Cy3-conjugated GAPDH siRNA (Ambion) was briefly mixed with 200 nM +36 
GFP and the resulting mixture was added to cells in serum-free media for 4 hours.  After 
washing the cells, flow cytometry revealed that +25 and +36 GFP delivered 100- and 1000-fold 
more siRNA into HeLa cells, respectively, than treatment with siRNA alone (Fig. 3B), and ~20-
fold more siRNA than was delivered with the common cationic lipid transfection reagent 
Lipofectamine 2000 (Fig. 3C).  In contrast, +15 GFP did not efficiently transfect siRNA into 
HeLa cells (Fig. 3B).  
In addition to HeLa cells, +36 GFP was also able to efficiently deliver siRNA in IMCD 
cells, 3T3-L preadipocytes, rat pheochromocytoma PC12 cells, and Jurkat T-cells, four cell lines 
that are resistant to siRNA transfection using Lipofectamine 2000 (1-4).  Treatment with 
Lipofectamine 2000 and Cy3-siRNA resulted in efficient siRNA delivery in HeLa cells, but no 
significant delivery of siRNA into IMCD, 3T3-L, PC12, or Jurkat cells (Fig. 3C).  Treatment of 
IMCD or 3T3-L cells with Fugene 6 (Roche), a different cationic lipid transfection agent, and 
Cy3-siRNA also did not result in significant siRNA delivery these cells (Supporting Information 
Fig. S4).  In contrast, treatment with +36 GFP and Cy3-siRNA resulted in significant siRNA 
levels in all five cell lines tested (Fig. 3C) that were 20- to 200-fold higher than siRNA levels 
resulting from Lipofectamine 2000 treatment.  Fluorescence microscopy of the adherent cell 
lines used in this study (HeLa, IMCD, and 3T3-L) reveal internalized Cy3-siRNA and +36 GFP 
in punctate foci that we presume to be endosomes (Fig. 3D).  These results collectively indicate 
that +36 GFP can effectively deliver siRNA into a variety of mammalian cell lines, including 
several that are poorly transfected by commonly used cationic lipid transfection reagents. 
When HeLa cells were treated with the a premixed solution containing 200 nM +36 GFP 
and 50 nM Cy3-siRNA in the presence of cytochalasin D or at 4°C, no internalized GFP or Cy3 
siRNA was observed (Supporting Information Fig. S3).  These data support a mechanism of McNaughton, Cronican, and Liu-7 
siRNA delivery that is dependent on endocytosis and actin polymerization, consistent with our 
mechanistic studies of +36 GFP in the absence of siRNA. 
 
Size and Cytotoxicity of +36 GFP–siRNA Complexes.  We analyzed +36 GFP–siRNA 
complexes by dynamic light scattering (DLS) using stiochiometric ratios identical to those used 
for transfection.  From a mixture containing 20 µM +36 GFP and 5 µM siRNA, we observed a 
fairly monodisperse population of particles with a hydrodynamic radius (Hr) of 880.6 ± 62.2 nm 
(Supporting Information Fig. S5A), consistent with microscopy data (Supporting Information 
Fig. S5B).  These observations demonstrate the potential for +36 GFP to form large particles 
when mixed with siRNA, a phenomena observed by previous researchers using cationic delivery 
reagents (12, 13). 
To assess the cytotoxicity of +36 GFP-siRNA complexes, we performed MTT assays on 
all five cell lines 24 hours after treatment with 0.2 to 2 μM +36 GFP and 50 nM siRNA.  These 
assays revealed no significant apparent cytotoxicity to HeLa, IMCD, 3T3-L, PC12, or Jurkat 
cells (Supporting Information Fig. S6).   
 
Gene Silencing With +36 GFP-Delivered siRNA.  While the above results demonstrate the 
ability of +36 GFP to deliver siRNA into a variety of mammalian cells, they do not establish the 
availability of this siRNA for gene silencing.  To evaluate the gene suppression activity of 
siRNA delivered with +36 GFP, we treated HeLa cells with a solution containing 50 nM of 
GAPDH-targeting siRNA and either ~2 µM Lipofectamine 2000 or 200 nM +36 GFP.  Cells 
were exposed to the siRNA transfection solution for four hours, then grown for up to four days. 
  In HeLa cells, observed decreases in GAPDH mRNA and protein levels indicate that both 
Lipofectamine 2000 and +36 GFP mediate efficient siRNA-induced suppression of GAPDH 
expression with similar kinetics.  GAPDH-targeting siRNA delivered with Lipofectamine 2000 
or +36 GFP resulted in a ~85% decrease in GAPDH mRNA levels after 72 hours (Fig. 4A), and a 
~75% decrease in GAPDH protein levels after 96 hours (Fig. 4B).  Similarly, delivery of β-actin-
targeting siRNA with either ~2 µM Lipofectamine 2000 or 200 nM +36 GFP resulted in a 
decrease in β-actin protein levels in HeLa cells of 70-78% for both transfection agents (Fig. 4B).  
In contrast to the efficiency of gene suppression in HeLa cells, treatment with 
Lipofectamine 2000 and 50 nM siRNA in IMCD, 3T3-L, PC12, and Jurkat cells effected no 
significant decrease in GAPDH protein levels (Fig. 4D), consistent with the resistance of these McNaughton, Cronican, and Liu-8 
four cell lines to cationic lipid-mediated transfection (Fig. 3C) (1-4).  Treatment with 200 nM 
+36 GFP and 50 nM siRNA, however, resulted in 44-60% suppression of GAPDH protein levels 
in IMCD, 3T3-L, and PC12 cells (Fig. 4D).  Despite efficient siRNA delivery by +36 GFP (Fig. 
3C), we observed no significant siRNA-mediated suppression of GAPDH expression in Jurkat 
cells (Fig. 4D). 
Together, these results indicate that +36 GFP and +36 GFP-HA2 are capable of 
delivering siRNA and effecting gene silencing in a variety of mammalian cells, including some 
cell lines that do not exhibit gene silencing when treated with siRNA and cationic lipid-based 
transfection agents. 
 
Stability of +36 GFP and Stability of RNA and DNA Complexed with +36 GFP.  In addition 
to generality across different mammalian cell types and low cytotoxicity, effective siRNA 
delivery agents should be resistant to rapid degradation and ideally should also extend siRNA 
lifetimes.  Treatment of +36 GFP with proteinase K, a robust, broad-spectrum protease, revealed 
that +36 GFP exhibits significant protease resistance compared with bovine serum albumin.  
While no uncleaved BSA remained one hour after proteinase K digestion, 68% of +36 GFP 
remained uncleaved after one hour, and 48% remained uncleaved after six hours (Supporting 
Information Fig. S7A).  We also treated +36 GFP with murine serum at 37 °C (Supporting 
Information Fig. S7B).  After six hours, no significant degradation was observed, suggesting its 
potential in vivo serum stability.  In comparison, when we incubated bovine serum albumin in 
mouse serum for the same period of time, we observed 71% degradation after three hours, and 
complete degradation by four hours.   
Next we assessed the ability of +36 GFP to protect siRNA and plasmid DNA from 
degradation.  We treated siRNA or siRNA pre-complexed with +36 GFP with murine serum at 
37 °C.  After three hours, only 5.9% of the siRNA remained intact in the sample lacking +36 
GFP, while 34% of the siRNA remained intact in the sample pre-complexed with +36 GFP 
(Supporting Information Fig S7C).  Similarly, while plasmid DNA was nearly completely 
degraded by murine serum after 30 minutes at 37 °C, virtually all plasmid DNA pre-complexed 
with +36 GFP remained intact after 30 minutes, and 84% of plasmid DNA was intact after one 
hour (Supporting Information Fig S7D).  These results together indicate that +36 GFP is capable 
of significantly inhibiting serum-mediated siRNA and plasmid DNA degradation.   
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Comparison of +36 GFP with Synthetic Cationic Peptides.  To probe the features of 
superpositively charged GFPs that impart their ability to deliver siRNA into cells, we compared 
the siRNA transfection ability of +36 GFP at 200 nM with that of a panel of synthetic cationic 
peptides at 200 nM or 2 µM.  This panel consisted of poly-(L)-Lys (a mixture containing an 
average of ~30 Lys residues per polypeptide), poly-(D)-Lys, Arg9, and a synthetic +36 peptide 
((KKR)11RRK) that contains the same theoretical net charge and Lys:Arg ratio as +36 GFP.  
MTT assays on HeLa cells treated with these synthetic polycations indicated low cytoxicity at 
the concentrations used, consistent with that of superpositively charged GFPs (Supporting 
Information Fig. S6B).  None of the four synthetic peptides tested, however, delivered a 
detectable amount of Cy3-siRNA into HeLa cells as assayed by flow cytometry, even when used 
at concentrations 10-fold higher than those needed for +36 GFP to effect efficient siRNA 
delivery or for +15 GFP to effect detectable siRNA delivery (Fig. 5).   
Coupled with our observation that +15 GFP exhibits low cell penetration and siRNA 
binding activity in comparison to +25 and +36 GFP (Figs. 3A and 3B), these results indicate that 
while GFP must be sufficiently positively charged to acquire the ability to enter cells and 
transfect siRNA efficiently, positive charge magnitude is not sufficient to confer transfection 
activity, and other features of +36 GFP lacking in the synthetic peptides tested are also required.   
 
+36 GFP-Mediated Transfection of Plasmid DNA.  Similar to the case with siRNA, we 
observed by gel-shift assay that +36 GFP forms a complex with plasmid DNA (Supporting 
Information Fig. S8).  To test if +36 GFP can deliver plasmid DNA to cells in a manner that 
supports plasmid-based gene expression, we treated HeLa, IMCD, 3T3-L, PC12, and Jurkat cells 
with a β-galactosidase expression plasmid premixed with Lipofectamine 2000, +36 GFP, or a C-
terminal fusion of +36 GFP and the hemagglutinin 2 (HA2) peptide, which has been reported to 
enhance endosome degradation (32).  After 24 hours, cells were analyzed for β-galactosidase 
activity using a fluorogenic substrate-based assay.   
  Consistent with our previous results (Figs. 3 and 4), Lipofectamine 2000 treatment 
resulted in significant β-galactosidase activity in HeLa cells, but only modest β-galactosidase 
activity in PC12 cells, and no detectable activity in any of the other three cell lines tested (Fig. 
6).  In contrast, plasmid transfection mediated by 2 μM +36 GFP-HA2 resulted in significant β-
galactosidase activity in HeLa, IMCD, and 3T3-L cells, and modest activity in PC12 cells (Fig. 
6).  Interestingly, treatment with plasmid DNA and 2 µM +36 GFP did not result in detectable β-McNaughton, Cronican, and Liu-10 
galactosidase activity (Fig. 6), suggesting that the hemagglutinin-derived peptide enhances DNA 
transfection or plasmid-based expression efficiency despite its lack of effect on siRNA-mediated 
gene silencing (Fig. 4D). 
  These results collectively indicate that +36 GFP-HA2 is able to deliver plasmid DNA 
into mammalian cells, including several cell lines resistant to cationic lipid-mediated 
transfection, in a manner that enables plasmid-based gene expression.  Higher concentrations of 
+36 GFP-HA2 are required to mediate plasmid DNA transfection than the amount of +36 GFP 
needed to induce efficient siRNA transfection. 
 
Discussion 
  We have characterized the cell penetration and nucleic acid delivery properties of three 
superpositively charged GFP variants with net charges of +15, +25, and +36.  We discovered 
that superpositive GFPs penetrate cells in a charge-dependent manner and that +36 GFP is 
capable of efficiently delivering siRNA into a variety of mammalian cell lines, including those 
resistant to cationic lipid-based transfection, with low cytotoxicity. 
Mechanistic studies revealed that +36 GFP enters cells through a clathrin- and caveolin-
independent endocytosis pathway that requires sulfated cell-surface proteoglycans and actin 
polymerization.  This delivery pathway differs from previously described strategies for nucleic 
acid delivery to eukaryotic cells that rely on cell-specific targeting to localize their nucleic acid 
cargo (15, 31, 33).  For use in cell culture and even in certain in vivo applications, a general, non-
cell type-specific approach to nucleic acid delivery may be a preferred alternative. 
In four of the five cell lines tested, +36 GFP-mediated siRNA delivery induced 
significant suppression of gene expression.  A +36 GFP-hemagglutinin peptide fusion mediated 
plasmid DNA transfection in a manner that enables plasmid-based gene expression in the same 
four cell lines.  The demonstrated ability to transfect RNA 21 base pairs in length as well as 
plasmid DNA over 5,000 bp in length suggests that +36 GFP and its derivatives may serve as 
fairly general nucleic acid delivery vectors.   
An important distinction between delivery methods that rely on the synthesis of 
covalently linked transfection agent-nucleic acid conjugates such as, carbon nanotube-siRNA 
(11), nanoparticle-siRNA (34), TAT peptide-siRNA (35), cholesterol-siRNA (36), dynamic 
polyconjugate-siRNA (37) and the use of +36 GFP is that the latter simply requires mixing the 
protein and nucleic acid together.  Moreover, the reagent described here is purified directly from McNaughton, Cronican, and Liu-11 
bacterial cells and used without chemical co-transfectants such as exogenous calcium or 
chloroquine. 
We previously reported that +36 GFP is thermodynamically almost as stable as sfGFP 
but unlike the latter is able to refold after boiling and cooling (17).  We now report that +36 GFP 
exhibits resistance to proteolysis, stability in murine serum, and significant protection of 
complexed siRNA in murine serum.  While additional studies are needed to further characterize 
the potential of +36 GFP for in vivo nucleic acid delivery, these features are consistent with 
several of the key requirements for such an application. 
 Taken together, these findings describe a new application of protein resurfacing— the 
potent delivery of nucleic acids into mammalian cells.  This unusual potency (38, 39) is 
complemented by low cytotoxicity, stability in mammalian serum, generality across various 
mammalian cell types including several that resist traditional transfection methods, the ability to 
transfect both small RNAs and large DNA plasmids, straightforward preparation from E. coli 
cells, and simple use by mixing with an unmodified nucleic acid of interest.  These qualities 
collectively suggest that superpositively charged proteins merit exploration as a new class of 
solutions to general nucleic acid delivery problems in mammalian cells.  
 
Materials and Methods 
See the Supporting Information for descriptions of additional experimental procedures. 
 
Expression and Purification of Supercharged GFP Proteins.  Supercharged GFP variants 
were purified using a variation on our previously reported method (17).  Briefly, GFP was 
overexpressed in BL21(DE3) E. coli.  Cells were lysed by sonication in 2 M NaCl in PBS, and 
purified as previously described (17).  Purified GFPs  (Supporting Information Fig. S9) were 
quantitated by absorbance at 488 nm assuming an extinction coefficient of 8.33 x 10
4 M
-1cm
-1 
(27).  Fluorescence emission spectra are shown in Supporting Information Fig. S10. 
 
Cationic Lipid-Based and GFP-Based Transfections.  Transfections using Lipofectamine 
2000 (Invitrogen) and Fugene 6 (Roche) were performed following the manufacturer’s protocol.  
Although the molecular weight of these reagents are not provided by the manufacturer, the 
concentration of Lipofectamine 2000 during transfection is 2 µg/mL and assuming the molecular 
weight of this cationic lipid is ≤ 1,000 Da, the concentration is ≥~2 µM.   McNaughton, Cronican, and Liu-12 
Cells were plated in a 12-well tissue culture plate at a density of 80,000 cells per well.  
After 12 hours at 37 °C, the cells were washed with 4 °C (PBS) and for HeLa, IMCD, 3T3-L, 
and PC12 cells the media were replaced with 500 μL of serum-free DMEM at 4 °C.  Jurkat cells 
were transferred from the culture plate wells into individual 1.5 mL tubes, pelleted by 
centrifugation, and resuspended in 500 μL of serum-free RPMI 1640 at 4 °C. 
A solution of GFP and either siRNA or plasmid DNA was mixed in 500 μL of either 4 °C 
DMEM (for HeLa, IMCD, 3T3-L, and PC12 cells) or 4 °C RPMI 1640 (for Jurkat cells).  After 5 
min at 25 °C, this solution was added to the cells and slightly agitated to mix.  After 4 hours at 
37 °C, the solution was removed from the cells and replaced with 37 °C media containing 10% 
FBS.  GAPDH-targeting Cy3-labeled siRNA and unlabeled siRNA were purchased from 
Ambion.  Plasmid transfections were performed using pSV-β-galactosidase (Promega).  β-
galactosidase activity was measured using the β-Fluor assay kit (Novagen) following the 
manufacturer’s protocol. 
 
Cell Imaging.  Four hours after treatment with GFP and Cy3-siRNA, cells were trypsinized and 
replated in medium containing 10% FBS on glass slides coated with Matrigel (BD Biosciences).  
After 24 hours at 37 °C, cells were fixed with 4% formaldehyde in PBS, stained with DAPI 
where indicated, and imaged with a Leica DMRB inverted microscope.  Exposure times for GFP 
and Cy3 were fixed at 350 msec and 500 msec, respectively. 
For experiments using small-molecule inhibitors, cells were plated on a glass-bottomed 
tissue culture plate (MatTek) and incubated with inhibitor for one hour at 37 °C, followed by 
treatment with 50 nM +36 GFP and inhibitor for an additional one hour at 37 °C.  The resulting 
cells were washed three times with PBS containing the inhibitor and 20 U/mL heparin to remove 
surface-associated GFP, with the exception that cells treated with 50 nM +36 GFP at 4° C were 
washed only one time with PBS containing 20 U/mL heparin to still allow a perimeter of some 
cell surface-bound GFP to be visible.   
Cells were imaged a 37 °C using an inverted microscope (Olympus IX70) in an epi-
fluorescent configuration with an oil-immersion objective (numerical aperture 1.45, 60X, 
Olympus).  GFP was excited with 488 nm light from an argon ion laser (Melles-Griot), and 
Alexa Fluor 647 was excited with a 633 nm helium-neon laser (Melles-Griot).   
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+36 GFP-siRNA Particle Size Characterization.  Dynamic light scattering was performed 
using a Protein Solution DynaPro instrument at 25 °C using 20 µM +36 GFP and 5 µM siRNA 
in PBS.  A purified 20-bp RNA duplex (5' GCAUGCCAUUACCUGGCCAU 3', from IDT) was 
used in these experiments.  Data was modeled to fit an isotrophic sphere.  5 µL of solution 
analyzed by DLS (20 µM +36 GFP and 5 µM siRNA in PBS) was imaged using a Leica DMRB 
inverted microscope.  
 
Acknowledgements 
We thank Sara Jones and Professor Xiaowei Zhuang for assistance with live cell imaging 
and for providing CHO and PGD-CHO cell lines.  Alan Saghatelian, Gregory Verdine, Matthew 
Shair, and Paula Nunes kindly provided 3T3-L, Jurkat, HeLa, and IMCD cells, respectively.  
This work was supported by the NIH/NIGMS (R01 GM 065400) and by the Howard Hughes 
Medical Institute.  J.J.C. is supported by a National Science Foundation Graduate Student 
Fellowship.McNaughton, Cronican, and Liu-14 
References 
1. Carlotti  F,  et al. (2004) Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 
adipocytes. Mol Ther 9, 209-217. 
2. Ma  H,  et al. (2002) Non-classical nuclear localization signal peptides for high efficiency 
lipofection of primary neurons and neuronal cell lines. Neuroscience 112, 1-5. 
3. McManus  MT,  et al. (2002) Small interfering RNA-mediated gene silencing in T 
lymphocytes. J Immunol 169, 5754-5760. 
4.  Strait KA, Stricklett PK, Kohan JL, Miller MB, Kohan DE (2007) Calcium regulation of 
endothelin-1 synthesis in rat inner medullary collecting duct. Am J Physiol Renal Physiol 
293, F601-606. 
5. Jantsch  J,  et al. (2008) Small interfering RNA (siRNA) delivery into murine bone 
marrow-derived dendritic cells by electroporation. J Immunol Methods 337, 71-77. 
6.  Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by 
virus-mediated RNA interference. Cancer Cell 2, 243-247. 
7. Stewart  SA, et al. (2003) Lentivirus-delivered stable gene silencing by RNAi in primary 
cells. RNA 9, 493-501. 
8. Akinc  A,  et al. (2008) A combinatorial library of lipid-like materials for delivery of 
RNAi therapeutics. Nat Biotechnol 26, 561-569. 
9.  Segura T, Hubbell JA (2007) Synthesis and in vitro characterization of an ABC triblock 
copolymer for siRNA delivery. Bioconjug Chem 18, 736-745. 
10.  Sokolova V, Epple M (2008) Inorganic nanoparticles as carriers of nucleic acids into 
cells. Angew Chem Int Ed Engl 47, 1382-1395. 
11.  Liu Z, Winters M, Holodniy M, Dai H (2007) siRNA delivery into human T cells and 
primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl 46, 2023-
2027. 
12.  Deshayes S, Morris MC, Divita G, Heitz F (2005) Cell-penetrating peptides: tools for 
intracellular delivery of therapeutics. Cell Mol Life Sci 62, 1839-1849. 
13.  Meade BR, Dowdy SF (2008) Enhancing the cellular uptake of siRNA duplexes 
following noncovalent packaging with protein transduction domain peptides. Adv Drug 
Deliv Rev 60, 530-536. 
14.  Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M (2007) Selective gene silencing in 
activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated 
antigen-1. Proc Natl Acad Sci U.S.A 104, 4095-4100. 
15. Song  E,  et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via 
cell-surface receptors. Nat Biotechnol 23, 709-717. 
16. Krutzfeldt  J,  et al. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 
685-689. 
17.  Lawrence MS, Phillips KJ, Liu DR (2007) Supercharging proteins can impart unusual 
resilience. J Am Chem Soc 129, 10110-10112. 
18.  Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human 
immunodeficiency virus. Cell 55, 1189-1193. 
19.  Green M, Loewenstein PM (1988) Autonomous functional domains of chemically 
synthesized human immunodeficiency virus tat trans-activator protein. Cell 55, 1179-
1188. 
20.  Thoren PE, Persson D, Karlsson M, Norden B (2000) The antennapedia peptide 
penetratin translocates across lipid bilayers - the first direct observation. FEBS Lett 482, 
265-268. McNaughton, Cronican, and Liu-15 
21.  Daniels DS, Schepartz A (2007) Intrinsically cell-permeable miniature proteins based on 
a minimal cationic PPII motif. J Am Chem Soc 129, 14578-14579. 
22.  Smith BA, Daniels DS, Coplin AE, Jordan GE, McGregor LM, Schepartz A (2008) 
Minimally cationic cell-permeable miniature proteins via alpha-helical arginine display. J 
Am Chem Soc 130, 2948-2949. 
23.  Fuchs SM, Raines RT (2007) Arginine grafting to endow cell permeability. ACS Chem 
Biol 2, 167-170. 
24.  Fuchs SM, Rutkoski TJ, Kung VM, Groeschl RT, Raines RT (2007) Increasing the 
potency of a cytotoxin with an arginine graft. Protein Eng Des Sel 20, 505-509. 
25.  Pedelacq JD, Cabantous S, Tran T, Terwilliger TC, Waldo GS (2006) Engineering and 
characterization of a superfolder green fluorescent protein. Nat Biotechnol 24, 79-88. 
26.  Payne CK, Jones SA, Chen C, Zhuang X (2007) Internalization and trafficking of cell 
surface proteoglycans and proteoglycan-binding ligands. Traffic 8, 389-401. 
27.  Veldhoen S, Laufer SD, Trampe A, Restle T (2006) Cellular delivery of small interfering 
RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of 
uptake and biological effect. Nucleic Acids Res 34, 6561-6573. 
28.  Hopkins CR, Trowbridge IS (1983) Internalization and processing of transferrin and the 
transferrin receptor in human carcinoma A431 cells. J Cell Biol 97, 508-521. 
29.  Fuchs SM, Raines RT (2004) Pathway for polyarginine entry into mammalian cells. 
Biochemistry 43, 2438-2444. 
30.  Baeuerle PA, Huttner WB (1986) Chlorate - a potent inhibitor of protein sulfation in 
intact cells. Biochem Biophys Res Commun 141, 870-877. 
31. Kumar  P,  et al. (2007) Transvascular delivery of small interfering RNA to the central 
nervous system. Nature 448, 39-43. 
32.  Lundberg P, El-Andaloussi S, Sutlu T, Johansson H, Langel U (2007) Delivery of short 
interfering RNA using endosomolytic cell-penetrating peptides. Faseb J 21, 2664-2671. 
33. Cardoso,  ALC.,  et al. (2007) siRNA delivery by a transferrin-associated lipid-based 
vector: a non-viral strategy to mediate gene silencing.  J. Gene Med., 9, 170-183. 
34.  Rosi, N., Giljohann, D., Thaxton, C., Lytton-Jean, A. Mirkin, C. (2006) Oligonucleotide-
modified gold nanoparticles for intracellular gene regulation. Science 312, 1027-1030.  
35.  Fisher, A., Ye, D., Sergueev, D., Fisher, M., Juliano, R. (2002) Evaluating the Specificity 
of Antisense Oligonucleotide Conjugates. J. Biol. Chem. 277, 22980-22984. 
36.  Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Vornlocher, HP (2004) Therapeutic 
silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 
432, 173-178. 
37.  Rozema, D., Lewis, D., Wakefield, D., Wong, S., Wolff, J. (2007) Dynamic 
polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad, 
Sci, U.S.A. 104, 12982-12987. 
38.  Deshayes, S, Simeoni, F, Morris, MC, Divita, G, Heitz, F (2007) Peptide-Mediated 
Delivery of Nucleic Acids into Mammalian Cells, Methods in Molecular Biology 386, 
299-308. 
39.  Lundberg, P, El-Andaloussi, S, Sütlü, T, Johansson, J, Langel, Ü (2007) Delivery of short 
interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. 21, 2664-2671. McNaughton, Cronican, and Liu-16 
 
 
 
 
Fig 1.  Supercharged GFP variants and their ability to penetrate cells.  (A) Calculated 
electrostatic surface potentials of GFP variants used in this study, colored from -25 kT/e (dark 
red) to +25 kT/e (dark blue).  (B) Flow cytometry analysis showing amounts of internalized GFP 
in HeLa cells treated with 200 nM of each superpositive GFP variant and washed three times 
with PBS containing heparin to remove cell surface-bound GFP.  (C) Flow cytometry analysis 
showing amounts of internalized +36 GFP (green) in HeLa, IMCD, 3T3-L, PC12, and Jurkat 
cells compared to untreated cells (black). 
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Fig 2. (A) Internalization of +36 GFP in HeLa cells after co-incubation for 1 hour at 37 °C.  (B) 
Inhibition of +36 GFP cell penetration in HeLa cells incubated at 4° C for 1 hour.  Cells were 
only partially washed to enable +36 GFP to remain partially bound to the cell surface.  (C) and 
(D) +36 GFP internalization under the conditions in (A) but in the presence of caveolin-
dependent endocytosis inhibitors filipin and nystatin, respectively.  (E) +36 GFP internalization 
under the conditions in (A) but in the presence of the clathrin-dependent endocytosis inhibitor 
chlorpromazine.  (F) Localization of Alexa Fluor 647-labeled transferrin (red) and +36 GFP 
(green) 20 minutes after endocytosis.  (G) Inhibition of +36 GFP internalization in HeLa cells in 
the presence of the actin polymerization inhibitor cytochalasin D.  (H) Inhibition of +36 GFP 
internalization in HeLa cells treated with 80 mM sodium chlorate.  (I) Internalization of +36 GFP 
in CHO cells incubated at 37° C for 1 hour. (J) Lack of +36 GFP internalization in PDG-CHO 
cells.  In (I) and (J) cell nuclei were stained with DAPI (blue).  The scale bar is 10 µm in (A)–(H) 
and 20 µm in (I)–(J). 
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Fig 3. (A) Gel-shift assay (31) to determine superpositive GFP:siRNA binding stoichiometry.  10 
pmoles of siRNA was mixed with various molar ratios of each GFP for 10 minutes at 25 °C, then 
analyzed by non-denaturing PAGE.  GFP-siRNA complexes were observed to remain in the 
loading well of the gel.  (B) Flow cytometry analysis showing levels of siRNA in HeLa cells 
treated with a mixture of 50 nM Cy3-siRNA and 200 nM of +15, +25, or +36 GFP, followed by 
three heparin washes to remove non-internalized GFP (Fig. S1).  (C) Flow cytometry analysis 
showing levels of Cy3-labeled siRNA delivered into HeLa, IMCD, 3T3-L, PC12, and Jurkat 
cells after incubation with a mixture of 50 nM Cy3-siRNA and either ~2 µM Lipofectamine 
2000 (blue) or 200 nM +36 GFP (green) in comparison to cells treated with siRNA without 
transfection reagent (black).  (D) Fluorescence microscopy images of stably adherent cell lines 
(HeLa, IMCD, and 3T3-L) 24 hours after a four-hour treatment with 200 nM +36 GFP and 50 
nM Cy3-siRNA.  Each image is an overlay of three channels: blue (DAPI stain), red (Cy3-
siRNA), and green (+36 GFP); yellow indicates the colocalization of red and green. Scale bar = 
10 µm. McNaughton, Cronican, and Liu-19 
 
 
 
 
Fig 4.  Suppression of GAPDH mRNA and protein levels resulting from siRNA delivery.  (A) 
GAPDH mRNA level suppression in HeLa cells 48, 72, or 96 hours after treatment with 50 nM 
siRNA and ~2 µM Lipofectamine 2000, or with 50 nM siRNA and 200 nM +36 GFP, as 
measured by RT-QPCR.  Suppression levels shown are normalized to β-actin mRNA levels; 0% 
suppression is defined as the mRNA level in cells treated with negative control siRNA.  (B) McNaughton, Cronican, and Liu-20 
GAPDH or β-actin protein level suppression in HeLa cells 48, 72, or 96 hours after treatment 
with siRNA and ~2 µM Lipofectamine 2000, or with siRNA and 200 nM +36 GFP.  (C) GAPDH 
protein level suppression in HeLa, IMCD, 3T3-L, PC12, and Jurkat cells 96 hours after treatment 
with 50 nM siRNA and ~2 µM Lipofectamine 2000, 200 nM +36 GFP, or 200 nM +36 GFP-
HA2.  Protein levels were measured by Western blot and are normalized to β-tubulin protein 
levels; 0% suppression is defined as the protein level in cells treated with negative control 
siRNA.  Values and error bars represent the mean and the standard deviation of three 
independent experiments in (A) and five independent experiments in (B) and (C). 
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Fig 5.  The siRNA transfection activities of a variety of cationic synthetic peptides compared 
with that of +15 and +36 GFP.  Flow cytometry was used to measure the levels of internalized 
Cy3-siRNA in HeLa cells treated for four hours with a mixture of 50 nM Cy3-siRNA and the 
peptide or protein shown. 
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Fig 6.  Plasmid DNA transfection into HeLa, IMCD, 3T3-L, PC12, and Jurkat cells by 
Lipofectamine 2000, +36 GFP, or +36 GFP-HA2.  Cells were treated with 800 ng pSV-β-
galactosidase plasmid and 200 nM or 2 µM of +36 GFP or +36 GFP-HA2 for four hours.  After 
24 hours, β-galactosidase activity was measured.  Values and error bars represent the mean and 
standard deviation of three independent experiments. 